Forum Financial Management LP Raises Holdings in Sanofi (NASDAQ:SNY)

Forum Financial Management LP raised its position in Sanofi (NASDAQ:SNY) by 76.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 66,827 shares of the company’s stock after buying an additional 28,879 shares during the quarter. Forum Financial Management LP’s holdings in Sanofi were worth $3,223,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of the business. Abel Hall LLC raised its holdings in Sanofi by 1.8% during the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock worth $530,000 after purchasing an additional 194 shares in the last quarter. Providence Capital Advisors LLC grew its holdings in Sanofi by 0.4% during the fourth quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company’s stock worth $2,653,000 after acquiring an additional 201 shares during the period. Keudell Morrison Wealth Management lifted its holdings in Sanofi by 1.7% in the fourth quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock valued at $624,000 after acquiring an additional 217 shares during the period. Bailard Inc. grew its stake in shares of Sanofi by 1.4% during the 4th quarter. Bailard Inc. now owns 16,359 shares of the company’s stock worth $789,000 after purchasing an additional 220 shares during the period. Finally, Old Port Advisors boosted its holdings in Sanofi by 0.6% during the fourth quarter. Old Port Advisors now owns 36,704 shares of the company’s stock worth $1,770,000 after buying an additional 232 shares in the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. BNP Paribas started coverage on Sanofi in a report on Tuesday. They issued an “outperform” rating and a $65.00 price target on the stock. The Goldman Sachs Group began coverage on shares of Sanofi in a research report on Friday, March 21st. They issued a “neutral” rating and a $65.00 price objective on the stock. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $63.33.

Sanofi Trading Up 0.7 %

SNY stock opened at $50.90 on Friday. Sanofi has a 52 week low of $45.22 and a 52 week high of $60.12. The business has a fifty day simple moving average of $54.79 and a 200-day simple moving average of $52.24. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The company has a market cap of $128.59 billion, a price-to-earnings ratio of 20.44, a PEG ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, equities research analysts expect that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Thursday, June 12th. Stockholders of record on Friday, May 9th will be paid a dividend of $2.0369 per share. This is a boost from Sanofi’s previous annual dividend of $1.48. This represents a dividend yield of 3.1%. The ex-dividend date is Friday, May 9th. Sanofi’s dividend payout ratio is 59.04%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.